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Purpose: Massive blood transfusios are uncommon. The goal of this study was to 
propose an ideal ratio for the blood component of massive hemorrhage treatment 
after review of five years of massive transfusion practice, in order to have the best 
possible clinical outcomes. Materials and Methods: We defined a ‘massive 
transfusionʼ as receiving 10 or more units of red blood cells in one day. A list of 
patients receiving a massive transfusion from 2004 to 2008 was generated using 
the electronic medical records. For each case, we calculated the ratio of blood 
components and examined its relationship to their survival. Results: Three hun-
dred thirty four patients underwent massive transfusion during the five years of the 
study. The overall seven-day hospital mortality for massive transfusion patients 
was 26.1%. Factors independently predictive of survival were a fresh-frozen plas-
ma (FFP)/packed red blood cell (pRBC) ratio≥1.1 with an odds ratio (OR) of 1.96 
(1.03-3.70), and elective admission with an OR of 2.6 (1.52-4.40). The receiver 
operation characteristic (ROC) curve suggest that a 1 : 1 : 1 ratio of pRBCs to FFP 
to platelets is the best ratio for survival. Conclusion: Fixing blood-component ra-
tios during active hemorrhage shows improved outcomes. Thus, the hospital blood 
bank and physician hypothesized that a fixed blood component ratio would help to 
reduce mortality and decrease utilization of the overall blood component.
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INTRODUCTION
Massive blood transfusion (massive transfusion) is the replacement of large amount 
of blood, for example transfusion that is equal to a complete blood volume replace-
ment over 24-hours.1 Massive transfusion has classically been defined as the ad-
ministration of more than 10 units of red blood cells (RBC) in a 24-hour period.2 In 
the 1970s, massive transfusion was associated with mortality rates more than 90%,3 
but, advances in care today, have led to a dramatic decrease in mortality, and mor-
tality rates between 30% and 70% are now common.4 Improved survival has been 
attributed to damage-control techniques, recognition and correction of coagulopa-
thy, patient re-warming, and improved overall resuscitation. However, because of 
the large volume of transfused blood components during massive transfusion epi-
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transfusion from January, 2004 to December, 2008 were 
found in the electronic medical record system and laborato-
ry information system. There had been no special transfu-
sion guideline in massive bleeding situation in this institu-
tion. Thrombelastography or thrombelastometry, which is 
now considered to be gold standard in monitoring massive 
bleeders, had not been available. Clinical data from the hos-
pital medical notes were used to check the diagnosis. The 
ratio of RBC to blood components was calculated for each 
case, and the relationship to survival was determined, and 
7-day outcome from starting infusion of first blood compo-
nent was set up as the end point, transfusion related mortal-
ity. Age, gender, admission, and diagnostic categories-intra-
abdominal bleeding, gastrointestinal bleeding, vascular 
surgery, trauma, cardiac surgery, liver related surgery, ob-
stetrics, orthopedic surgery, etc.-were entered into a stepwise 
logistic regression model and individual comparisons were 
made using the Mann-Whitney U-test for non-parametric 
data and the Student’s t-test for parametric data. Statistical 
analysis was performed using the Statistical Package for So-
cial Sciences version 15.0 (SPSS inc., Chicago, IL, USA). 
 
RESULTS
From 2004 to 2008, 314 patients received a massive trans-
fusion over the 5 years of the study. The mean age was 54 
years, with 196 men and 118 women. The overall 7-day hos-
pital mortality for patients receiving a massive transfusion 
was 26.1%. Patients receiving a massive transfusion ac-
counted for 5,630 units of RBCs, representing 2.6% of all 
red cell transfusions during the study period. The massive 
transfusion group also accounted for 3.6% of FFP and 0.6% 
of platelets. The cryoprecipitate used in massive transfu-
sions accounted for 12.2% of total cryoprecipitate transfu-
sions (Table 1). Baseline demographic data comparing sur-
vivors with non-survivors in the massive transfusion group 
are presented in Table 2. 
These groups were entered into the logistic regression 
model for survival, together with data on the diagnostic cat-
egories of gender, age, plasma and platelet use, and elective 
or emergency admission status (Table 3). Baseline bio-
chemistry and hematologic results were not included in the 
regression analysis because of missing data. 
Independently predictive factors of survival were an FFP: 
RBC ratio≥1.1 with an odds ratio (OR) of 1.96 (1.03-3.70), 
and elective admission with an OR of 2.6 (1.53-4.40). 
sodes, guidance during bedside administration is needed to 
optimize patient outcome and blood component use. Re-
cently, studies of massive transfusion experiences of the 
U.S. military have advocated the use of aggressive repletion 
of clotting factors in the form of fresh-frozen plasma (FFP), 
platelets, and cryoprecipitate in patients receiving massive 
transfusion.5,6 This has led to changes in transfusion practic-
es, especially to earlier and greater use of plasma and plate-
lets during massive transfusion, including component thera-
py at a 1 : 1 : 1 ratio of RBCs to FFP to platelets.2 In non-
military centers, where aggressive component therapy is 
limited due to patients’ variable conditions, implementation 
of these transfusion ratios is difficult without a well-de-
signed protocol. Hospitals that serve an older and more het-
erogeneous population have patients with co-morbid dis-
eases that require drugs that can affect the hemostatic 
system. The study of transfusion in this setting is difficult. A 
recent review found that less than 10 institutions are using 
protocols for massive transfusion worldwide,2 even though 
many institutions that follow massive transfusion protocols 
have reduced mortality rates, primarily because of an in-
creased FFP : RBC ratio.4,7-9 Few studies have examined 
massive transfusion outcomes in a systematic manner be-
cause of the sporadic and unpredictable nature of massive 
transfusion.10
The goal of this paper was to propose beneficial blood 
component ratio, based on scientific evidence, that will serve 
as a model for the treatment concept of massive hemor-
rhage by retrospectively reviewing the last five years of 
massive transfusion practice at a tertiary care teaching hos-
pital in Seoul, South Korea. 
MATERIALS AND METHODS
This observational study was conducted at a tertiary teaching 
hospital which has 2,075 beds and uses an average of 43,900 
RBC units per year. The RBCs included packed RBC, 
washed RBC, on leukocyte-depleted RBC. In the blood 
bank, RBC-whether leukocyte-depleted or not, FFP and 
platelet concentration were ready to issue for 24 hours. In 
emergency situation, Rh negative O type RBCs would be is-
sued immediately. Average time of 20 minutes was taken for 
issuing in emergent type and crossmatched blood product.
Massive transfusion was defined as receiving 10 or more 
units of RBCs, whether leukocyte-depleted or not, in 24 
hours. Using this definition, patients receiving a massive 
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RBC ratio had a median of 0.62, and was 0.72 among non-
survivors and 0.59 among survivors. A similar pattern was 
found for platelet use. The ratio of platelets to RBCs in non-
survivors had a median of 0.61, as compared to a median of 
Table 4 shows RBCs and other blood components given 
to survivors and non-survivors, and gives the ratios of the 
clotting components, FFP, cryoprecipitate and platelets, to 
RBC per massive transfusion episode. The overall FFP to 
 Table 1. Transfused Product Number of Massive Transfusion Compared to the Whole Transfused Population
Blood components
Number of units transfused
Massive transfusion group All transfused group in 2004-2008
RBC 5,630 (2.6)* 219,121
FFP 3,406 (3.6)*   93,547
Platelets 3,002 (0.6)* 522,316
Cryoprecipitate            222 (12.2)*     1,817
Total  12,291 (1.5)* 836,900
RBC, red blood cells; FFP, fresh frozen plasma.
*Percent of massive transfusion group per whole transfused units.
Table 2. Baseline Demographic Data for Survivors and Non-Survivors from the Massive Transfusion Group
Total Non-survivor Survivor
p value
N % N % N %
Total 314 82 26.1 232 73.9
Age (mean, yrs)    52.5    53.2    52.2
Gender 0.071
    Male 196 62.4 58 70.7 138 59.5 
    Female 118 37.6 24 29.3 94 40.5 
Admission category 0.001
    Emergency 157 50.0 55 67.1 102 44.0 
    Elective 157 50.0 27 32.9 130 56.0 
Operation 92 29.3 40 48.8 52 22.4 <0.001
Diagnosis category
    Intra-abdominal bleeding 35 11.1   5   6.1 30 12.9 0.090
    Gastrointestinal bleeding 59 18.8 29 35.4 30 12.9 <0.001
    Vascular 44 14.0 13 15.9 31 13.4 0.587
    Trauma 44 14.0 13 15.9 31 13.4 0.587
    Cardiac 55 17.5 12 14.6 43 18.5 0.418
    Liver 21   6.7   6   7.3 15   6.5 0.799
    Obstetric 20   6.4   2   2.4 18   7.8 0.089
    Unknown/other 24   7.6   2   2.4 22   9.5 0.038
    Orthopedic   9   2.9   0   0.0   9   3.9 0.070
    Skin/soft tissue   3   1.0   0   0.0   3   1.3 0.301
Table 3. Conditional Logistic Regression Analysis
Factors associated with mortality Odds ratio 95% confidence intervals p value
Age over 65 years old 0.98 0.56-1.72 0.945
Male gender 1.65 0.96-2.83 0.071
Liver disease 1.14 0.43-3.05 0.791
Cardiovascular disease 0.87 0.50-1.50 0.609
Emergency admission 2.60 1.53-4.40 0.027
FFP : RBC ratio <1.1 0.48 0.26-0.90 0.020
FFP : RBC ratio <1.5 0.33 0.12-0.91 0.026
PLT : RBC ratio <1.1 0.92 0.44-1.94 0.831
PLT : RBC ratio <1.5 1.22 0.43-3.41 0.708
FFP, fresh frozen plasma; RBC, red blood cells; PLT, platelet concentrate.
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for best survival.  ROC curve analysis showed that the sur-
vival rate increased as the FFP : RBC ratio increased.  For a 
ratio of 1, the survival rate was expected to be 85%, and for 
a ratio of 0.67, or FFP : RBC=1 : 1.5, the survival rate was 
expected to be 66%. Increased platelet : RBC ratios also 
correlated with increased survival rates. At a cut-off of 1, 
the expected survival rate was 85%. 
0.56 in survivors. However, these data might mask poten-
tial effects of clotting component ratios that were much less 
than, or much greater than, 1 : 1. To further explore this 
possibility, we categorized the clotting component to RBC 
ratios case by case, as <0.9, 0.9-1.1, or >1.1 (Table 5). Fig. 
1 shows receiver operation characteristic (ROC) curves of 
FFP : RBC, and platelet : RBC that suggest cut-off values 
Table 4. Comparison of Blood Components Used by Survivors and Non-Survivors
Non-survivor Survivor
p value
 Mean Range Mean Range
Component used per massive transfusion episode
    RBC 21.3 10-62 16.7 10-73 <0.001
    FFP 14.9   0-92 9.4   0-35 <0.001
    Platelets 12.0   0-16 8.7   0-48   0.003
    Cryoprecipitate   0.6 0-6 0.8   0-16   0.562
Ratios
    FFP : RBC     0.72    0-2.9   0.58    0-2.2   0.031
    Platelets : RBC     0.61    0-2.3   0.56    0-2.4   0.419
    Cryoprecipitate : RBC     0.04    0-0.8   0.04    0-0.9   0.941
RBC, red blood cells; FFP, fresh frozen plasma. 
Table 5. Comparison of Categories of Blood Component Ratios between Survivors and Non-Survivors
Total Non-survivor Survivor
N % N % N %
FFP : RBC ratio
    High (>1.1)   50 15.9 20 24.4   22   9.5
    Equal (0.9-1.1)   32 10.2 10 12.2   30 12.9
    Low (<0.9) 232 73.9 52 63.4 180 77.6
Platelet : RBC ratio
    High (>1.1)   38 12.1 10 12.2   15   6.5
    Equal (0.9-1.1)   25   8.0   9 11.0     9   3.9
    Low (<0.9) 251 79.9 63 76.8 156 67.2
Total 314 100.0 82 100.0 232 100.0
FFP, fresh frozen plasma; RBC, red blood cells. 
Fig. 1. ROC curves of each blood product ratio. ROC, receiver operation characteristic. 
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the use of FFP, platelets, and cryoprecipitate on the basis of 
coagulation tests and platelet count: a fixed blood component 
ratio is thought to be necessary to prevent coagulopathy, 
which can result from underestimating the clotting factor re-
quirements or delaying the transfusion of clotting factor com-
ponent.12 The majority of our patients (64.0%) received a low 
FFP : RBC and platelet : RBC ratio. In contrast, however, the 
current trauma literature focuses on changes in blood compo-
nent ratio as a means to reduce mortality.5 In the U.S. mili-
tary, the practice of rapidly correcting coagulopathy suggests 
that a fixed FFP : RBC ratio in massive transfusion proto-
cols is optimal in trauma centers.5,13,14 However, conflicting 
evidence exists regarding the benefit of a fixed ratio in gen-
eral practice hospitals. Although recent studies have sug-
gested that high FFP : RBC ratios do not translate into de-
creased mortality,15,16 other studies, including our own, show 
improved mortality rates with a high FFP : RBC ratio.8,17,18
Although analysis suggests that the FFP : RBC ratio is an 
important variable in care, other benefits are rarely dis-
cussed. Some studies have used computer modeling to as-
sess the effect of protocol-based care, and shown optimal 
replacement ratios of 2 : 3 for FFP : RBC and 8 : 10 for plate-
lets : RBC.19
Some investigators have generated massive transfusion 
or exsanguinations protocols, while others have raised con-
cerns over the potential increase in morbidity associated 
with the transfusion of a large number of blood compo-
nents.20-22 One study, however, confirmed that the use of 
transfusion protocols directly correlates with improved sur-
vival rate and reduced number of complications and organ 
failures in critically injured patients who receive massive 
transfusions.23
The transfusion of blood and clotting components has a 
risk, and recent evidence suggests that transfusion poses 
more risks for critically ill patients.24 Acute lung injury and 
other immunomodulatory effects related to transfusions are 
receiving increasing attention. These effects can result from 
the transfusion of any blood components, but plasma-rich 
components, such as FFP and platelets, have in particular 
been implicated.25 Clinical studies have provided an evi-
dence that a higher ratio of FFP : RBC is associated with an 
improved outcome.26 Overuse of blood components may be 
associated with other transfusion-related complications, but 
they may be reduced by an early approach according to a 
specific protocol.27 
 Our proposed fixed component ratio uses an FFP : RBC 
: platelet ratio of 1 : 1 : 1. Furthermore, we hope to improve 
DISCUSSION
Massive transfusion is an uncommon event, occurring in 
only 0.3% cases of blood component transfusion, but pa-
tients who received massive transfusion accounted for 
4.8% of total blood component resources, and sustained a 
mortality rate of 26.1% in this study. This was lower than 
the 30.3% mortality seen for massive transfusion patients at 
the same institute in 1991.11 The reduced mortality rate may 
be due to advanced patient care techniques and improved 
knowledge about blood transfusion. Nevertheless, there is 
yet no special guideline or protocol about massive transfu-
sion at this institute, as mentioned earlier. 
Riskin, et al.4 suggested that implementation of a massive 
transfusion protocol and fixed blood component ratio are 
associated with reduced mortality and mean time to first 
blood component. Furthermore, hemostatic resuscitation 
based on hemostatic control as guided by thromboelastog-
raphy, has recently been associated with improved surviv-
al.7  However, these technique, thromboelastography or ro-
tation thromboelastometry, is not available at all institutions 
in where massively bleeding patients are treated. The fixed 
ratio blood component therapy is not superior to cell-based 
model. Nevertheless, at the institution which is not pre-
pared for the proper hemostatic control monitoring system, 
the fixed blood component therapy might be useful. There-
fore, we propose a proper blood component ratio, without 
cell-based whole blood viscoelastcal assays, based on our 
five-year evaluation of massive transfusion patients at a ter-
tiary care teaching hospital.
The first goal of the protocol is to improve patient outcome 
by establishing a proper fixed blood component ratio for 
emergency situations. Overall usage of blood component 
during massive transfusion in the non-survivor group was 
significantly higher than in the survivor group (p<0.001), 
which might have resulted from poorer condition of pa-
tients in this group. In this study, emergency admission and 
the number of units of platelets transfused were indepen-
dent risk factors for 7-day hospital mortality. The total 
length of hospital stay, intensive care unit stay and infection 
status were not evaluated, and the use of anticoagulant or 
aspirin before and after admission was not considered be-
cause of limits of information. 
Management of massive blood loss has traditionally been 
focused on the restoration of blood volume, initially with 
crystalloid or colloid fluids, then with RBCs, followed by 
Seoyoung Yoon, et al.
Yonsei Med J   http://www.eymj.org   Volume 52   Number 3   May 2011474
Maggio PM, et al. Massive transfusion protocols: the role of ag-
gressive resuscitation versus product ratio in mortality reduction. J 
Am Coll Surg 2009;209:198-205.
5. Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, 
Beekley AC, et al. The ratio of blood products transfused affects 
mortality in patients receiving massive transfusions at a combat 
support hospital. J Trauma 2007;63:805-13.
6. Bormanis J. Development of a massive transfusion protocol. 
Transfus Apher Sci 2008;38:57-63.
7. Johansson PI, Stensballe J. Effect of Haemostatic Control Resus-
citation on mortality in massively bleeding patients: a before and 
after study. Vox Sang 2009;96:111-8.
8. Johansson PI, Bochsen L, Stensballe J, Secher NH. Transfusion 
packages for massively bleeding patients: the effect on clot forma-
tion and stability as evaluated by Thrombelastograph (TEG). 
Transfus Apher Sci 2008;39:3-8.
9. Johansson PI. The blood bank: from provider to partner in treat-
ment of massively bleeding patients. Transfusion 2007;47:176S-
81S.
10. Hardy JF, de Moerloose P, Samama CM. Massive transfusion and 
coagulopathy: pathophysiology and implications for clinical man-
agement. Can J Anaesth 2006;53:S40-58.
11. Lee MK, Kim HO, Hong SG, Kwon OH, Kim JJ. Massive transfu-
sion in Severance hospital. Korean J Blood Transfus 1993;4:23-8.
12. Donaldson MD, Seaman MJ, Park GR. Massive blood transfu-
sion. Br J Anaesth 1992;69:621-30.
13. Holcomb JB, Jenkins D, Rhee P, Johannigman J, Mahoney P, 
Mehta S, et al. Damage control resuscitation: directly addressing 
the early coagulopathy of trauma. J Trauma 2007;62:307-10.
14. Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen 
plasma, cryoprecipitate, and platelet transfusion in trauma. J Trau-
ma 2006;60:S51-8.
15. Kashuk JL, Moore EE, Johnson JL, Haenel J, Wilson M, Moore 
JB, et al. Postinjury life threatening coagulopathy: is 1:1 fresh fro-
zen plasma:packed red blood cells the answer? J Trauma 2008;65: 
261-70.
16. Scalea TM, Bochicchio KM, Lumpkins K, Hess JR, Dutton R, 
Pyle A, et al. Early aggressive use of fresh frozen plasma does not 
improve outcome in critically injured trauma patients. Ann Surg 
2008;248:578-84.
17. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzabal 
LA, Schreiber MA, et al. Increased plasma and platelet to red 
blood cell ratios improves outcome in 466 massively transfused 
civilian trauma patients. Ann Surg 2008;248:447-58.
18. Sperry JL, Ochoa JB, Gunn SR, Alarcon LH, Minei JP, Cuschieri 
J, et al. An FFP:PRBC transfusion ratio >/=1:1.5 is associated 
with a lower risk of mortality after massive transfusion. J Trauma 
2008;65:986-93.
19. Hirshberg A, Dugas M, Banez EI, Scott BG, Wall MJ Jr, Mattox 
KL. Minimizing dilutional coagulopathy in exsanguinating hem-
orrhage: a computer simulation. J Trauma 2003;54:454-63.
20. Dunne JR, Riddle MS, Danko J, Hayden R, Petersen K. Blood 
transfusion is associated with infection and increased resource uti-
lization in combat casualties. Am Surg 2006;72:619-25.
21. Sarani B, Dunkman WJ, Dean L, Sonnad S, Rohrbach JI, Gracias 
VH. Transfusion of fresh frozen plasma in critically ill surgical 
patients is associated with an increased risk of infection. Crit Care 
Med 2008;36:1114-8.
22. Vamvakas EC. Platelet transfusion and postoperative infection in 
cardiac surgery. Transfusion 2007;47:352-4.
communication between the blood bank and clinical physi-
cian to keep the proper ratio and to decrease the time need-
ed to prepare transfusion components. O’Keeffe, et al.28 an-
alyzed time and cost before and after implementing a 
massive transfusion protocol, and concluded that the protocol 
offered a number of benefits, including fewer blood compo-
nent transfusions, improved time to transfusion, and de-
creased blood bank and hospital charges. The fixed blood-
component volume ratios for use during active hemorrhage 
might allow the number of RBC units administered to be 
used as a surrogate for blood loss and primary treatment ef-
fects. The relationship between blood loss and administered 
blood volume will be most direct for a large number of 
RBC units. The usage of the blood component during mas-
sive transfusion in the non-survivor group was significantly 
higher than in the survivor group (p<0.001).
These approaches are in alignment with the findings of 
Johansson9 who concluded that the optimal transfusion by 
proper monitoring improved the survival of massively bleed-
ing patients. Therefore, the blood banks should be encour-
aged to remove impediments to rapid issuing of blood com-
ponent. In addition, the medical/surgical department should 
discuss the feasibility of the fixed blood component ratio 
and the consequences of its use. Finally, the hospital blood 
bank should realize that the fixed blood component ratio 
measures would improve the access to blood components, 
reduce mortality, and decrease unnecessary blood compo-
nent utilization. 
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